Dobi Medical completes private placement
Financial coffers at Dobi Medical have swelled following the private placement of $5.16 million in shares of its Series A Preferred stock and warrants. The shares carry a dividend of 8% per year and are convertible into 2,580,667 shares of common stock.
Financial coffers at Dobi Medical have swelled following the private placement of $5.16 million in shares of its Series A Preferred stock and warrants. The shares carry a dividend of 8% per year and are convertible into 2,580,667 shares of common stock. Proceeds from the transaction will be used to build and begin internationally marketing the company's ComfortScan system, a noninvasive optical imaging system designed for use in the detection and management of breast cancer.
Financial results for the company in the second fiscal quarter of 2004, ended June 30, show a net loss of $1.6 million, or 4¢ per share, compared with a net loss of $1.1 million, or 6¢ per share in the same quarter last year. For the first six months of fiscal 2004, net loss was $3.0 million, or 8¢ per share, compared with a net loss of $2.3 million, or 12¢ per share in the previous year's period.
Emerging AI Mammography Model May Enhance Clarity for Initial BI-RADS 3 and 4 Classifications
May 21st 2025In a study involving over 12,000 Asian women, researchers found that an artificial intelligence (AI) model converted over 83 percent of false positives in patients with initial BI-RADS 3 and 4 assessments into benign BI-RADS categories.
Study: Abbreviated Breast MRI Offers Equivalent Accuracy to mpMRI for Women with Dense Breasts
May 20th 2025Emerging research suggests that abbreviated breast MRI offers comparable sensitivity and specificity as multiparametric MRI in women with extremely dense breasts with a nearly 50 percent reduction in reading time for radiologists.
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.
